Connect Biopharma

Yahoo Finance • 4 months ago

Discovering Connect Biopharma Holdings And 2 Other Promising Penny Stocks

As the U.S. stock market continues to rally, with major indexes like the S&P 500 and Dow Jones nearing record highs, investors are increasingly looking for opportunities in less traditional areas. Penny stocks, though often considered a re... Full story

Yahoo Finance • 5 months ago

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment... Full story

Yahoo Finance • 7 months ago

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inf... Full story

Yahoo Finance • 7 months ago

Which stocks are moving before the opening bell on Wednesday?

Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT STI [https://www.chartmill.com/st... Full story

Yahoo Finance • 8 months ago

Connect Biopharma GAAP EPS of -$0.23

* Connect Biopharma press release [https://seekingalpha.com/pr/20199580-connect-biopharma-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:CNTB [https://seekingalpha.com/symbol/CNTB]): Q2 GAAP EPS of -$0... Full story

Yahoo Finance • 9 months ago

Connect Biopharma stock rating reiterated as Outperform by Northland

Investing.com - Northland has reiterated its Outperform rating on Connect Biopharma Holdings Ltd (NASDAQ:CNTB), maintaining its price target of $7.50 per share. The stock has shown remarkable momentum, surging 37% in the past week and 45... Full story

Yahoo Finance • 9 months ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammat... Full story

Yahoo Finance • 9 months ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment... Full story

Yahoo Finance • 9 months ago

Connect Biopharma Regains Nasdaq Compliance On Minimum Bid Price

(RTTNews) - Connect Biopharma Holdings Limited (CNTB), a clinical-stage biopharmaceutical company focused on inflammatory disease treatments, announced that it has regained compliance with Nasdaq's minimum bid price requirement under Listi... Full story

Yahoo Finance • 9 months ago

Connect Biopharma regains Nasdaq compliance with $1 minimum bid price

SAN DIEGO - Connect Biopharma Holdings Limited (NASDAQ:CNTB), a $90 million market cap clinical-stage biopharmaceutical company, has regained compliance with Nasdaq’s minimum bid price requirement, the company announced Thursday. The comp... Full story

Yahoo Finance • 9 months ago

Connect Biopharma's partner submits new drug application in China

SAN DIEGO - Connect Biopharma Holdings Limited (NASDAQ:CNTB), a biotech company with a market capitalization of $63 million and a strong financial health rating according to InvestingPro, announced Wednesday that its collaborator Simcere P... Full story

Yahoo Finance • 10 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data suppo... Full story

Yahoo Finance • 10 months ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma an... Full story

Yahoo Finance • 11 months ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerba... Full story

Yahoo Finance • last year

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademiki... Full story

Yahoo Finance • last year

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and c... Full story

Yahoo Finance • 2 years ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Simcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater China Connect Biopharma retains rights to develop and commercialize rademikibart in all other markets and co... Full story

Yahoo Finance • 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose ma... Full story

Yahoo Finance • 2 years ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the li... Full story

Yahoo Finance • 3 years ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Key data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitisTopline results from Global Phase 2 trial in asthmaCash b... Full story